Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial

Clin Infect Dis. 2024 Nov 22;79(5):1172-1181. doi: 10.1093/cid/ciae333.

Abstract

Background: Few antiviral therapies have been studied in patients with coronavirus disease 2019 (COVID-19) and kidney impairment. Herein, the efficacy, safety, and pharmacokinetics of remdesivir, its metabolites, and sulfobutylether-β-cyclodextrin excipient were evaluated in hospitalized patients with COVID-19 and severe kidney impairment.

Methods: In REDPINE, a phase 3, randomized, double-blind, placebo-controlled study, participants aged ≥12 years hospitalized for COVID-19 pneumonia with acute kidney injury, chronic kidney disease, or kidney failure were randomized 2:1 to receive intravenous remdesivir (200 mg on day 1; 100 mg daily up to day 5) or placebo (enrollment from March 2021 to March 2022). The primary efficacy end point was the composite of the all-cause mortality rate or invasive mechanical ventilation rate through day 29. Safety was evaluated through day 60.

Results: Although enrollment concluded early, 243 participants were enrolled and treated (remdesivir, n = 163; placebo, n = 80). At baseline, 90 participants (37.0%) had acute kidney injury (remdesivir, n = 60; placebo, n = 30), 64 (26.3%) had chronic kidney disease (remdesivir, n = 44; placebo, n = 20), and 89 (36.6%) had kidney failure (remdesivir, n = 59; placebo, n = 30); and 31 (12.8%) were vaccinated against COVID-19. Composite all-cause mortality or invasive mechanical ventilation rates through day 29 were 29.4% and 32.5% in the remdesivir and placebo group, respectively (P = .61). Treatment-emergent adverse events were reported in 80.4% for remdesivir versus 77.5% for placebo, and serious adverse events in 50.3% versus 50.0%, respectively. Pharmacokinetic plasma exposure to remdesivir was not affected by kidney function.

Conclusions: Although the study was underpowered, no significant difference in efficacy was observed between treatment groups. REDPINE demonstrated that remdesivir is safe in patients with COVID-19 and severe kidney impairment.

Clinical trials registration: EudraCT 2020-005416-22; Clinical Trials.gov NCT04745351.

Keywords: COVID-19; SARS-CoV-2; kidney impairment; remdesivir.

Publication types

  • Randomized Controlled Trial
  • Clinical Trial, Phase III

MeSH terms

  • Acute Kidney Injury / chemically induced
  • Adenosine Monophosphate* / administration & dosage
  • Adenosine Monophosphate* / adverse effects
  • Adenosine Monophosphate* / analogs & derivatives
  • Adenosine Monophosphate* / pharmacokinetics
  • Adenosine Monophosphate* / therapeutic use
  • Adult
  • Aged
  • Aged, 80 and over
  • Alanine* / adverse effects
  • Alanine* / analogs & derivatives
  • Alanine* / pharmacokinetics
  • Alanine* / therapeutic use
  • Antiviral Agents* / adverse effects
  • Antiviral Agents* / pharmacokinetics
  • Antiviral Agents* / therapeutic use
  • COVID-19 Drug Treatment*
  • COVID-19* / complications
  • COVID-19* / mortality
  • Double-Blind Method
  • Female
  • Hospitalization*
  • Humans
  • Male
  • Middle Aged
  • Respiration, Artificial
  • SARS-CoV-2*
  • Treatment Outcome

Substances

  • remdesivir
  • Alanine
  • Adenosine Monophosphate
  • Antiviral Agents

Associated data

  • ClinicalTrials.gov/NCT04745351

Grants and funding